Alizyme updates on Ph III R&D program in preparation for a busy 2008
Since completing a round of management changes late last year, which included the appointment of Tim McCarthy as chief executive (Marketletter December 11, 2006), UK-based biopharmaceutical group Alizyme has, in 2007, set about expanding both its R&D efforts and commercial partnering activities. With two drugs currently in Phase III development and a two others performing well in Phase II clinical studies, 2008 looks set to be a be a busy year for the Cambridgeshire-headquartered firm.
Renzapride makes progress at Ph III
Earlier this year, Alizyme announced that it has agreed the design of second Phase III trial of its developmental irritable bowel syndrome treatment renzapride with the US Food and Drug Administration (Marketletter July 18).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze